2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective.

My involvement with the field of cannabinoids spans close to 3 decades and covers a major part of my scientific career. It also reflects the robust progress in this initially largely unexplored area of biology. During this period of time, I have witnessed the growth of modern cannabinoid biology, starting from the discovery of its two receptors and followed by the characterization of its endogenous ligands and the identification of the enzyme systems involved in their biosynthesis and biotransformation. I was fortunate enough to start at the beginning of this new era and participate in a number of the new discoveries. It has been a very exciting journey. With coverage of some key aspects of my work during this period of "modern cannabinoid research," this Award Address, in part historical, intends to give an account of how the field grew, the key discoveries, and the most promising directions for the future.

[1]  A. Makriyannis,et al.  Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  S. Nikas,et al.  C-ring cannabinoid lactones: a novel cannabinergic chemotype. , 2014, ACS medicinal chemistry letters.

[3]  S. Nikas,et al.  Controlled-deactivation cannabinergic ligands. , 2013, Journal of medicinal chemistry.

[4]  A. Makriyannis,et al.  Therapeutic Opportunities through the Modulation of Endocannabinoid Transport , 2013, Pharmaceutical regulatory affairs : open access.

[5]  Karl Gruber,et al.  Conformational Plasticity and Ligand Binding of Bacterial Monoacylglycerol Lipase , 2013, The Journal of Biological Chemistry.

[6]  A. Makriyannis,et al.  Active-site inhibitors modulate the dynamic properties of human monoacylglycerol lipase: a hydrogen exchange mass spectrometry study. , 2013, Biochemistry.

[7]  Rishi Sharma,et al.  Targeting the Endocannabinoid System for Neuroprotection: A 19F-NMR Study of a Selective FAAH Inhibitor Binding with an Anandamide Carrier Protein, HSA , 2013, Journal of pharmaceutics & pharmacology.

[8]  Anna L. Bowman,et al.  Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire , 2013, Protein science : a publication of the Protein Society.

[9]  Anna L. Bowman,et al.  Novel adamantyl cannabinoids as CB1 receptor probes. , 2013, Journal of medicinal chemistry.

[10]  B. Cravatt,et al.  Dual Inhibition of Endocannabinoid Catabolic Enzymes Produces Enhanced Antiwithdrawal Effects in Morphine-Dependent Mice , 2013, Neuropsychopharmacology.

[11]  M. Babu,et al.  Molecular signatures of G-protein-coupled receptors , 2013, Nature.

[12]  S. Nikas,et al.  The Interaction of Fatty Acid Amide Hydrolase (FAAH) Inhibitors with an Anandamide Carrier Protein Using 19F-NMR , 2013, The AAPS Journal.

[13]  Anna L. Bowman,et al.  Sulfonyl fluoride inhibitors of fatty acid amide hydrolase. , 2012, Journal of medicinal chemistry.

[14]  Anna L. Bowman,et al.  Biochemical and Mass Spectrometric Characterization of Human N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition , 2012, PloS one.

[15]  Anna L. Bowman,et al.  C3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor. , 2012, Bioorganic & medicinal chemistry letters.

[16]  G. A. Bezerra,et al.  Crystal structure of monoacylglycerol lipase from Bacillus sp. H257 , 2012 .

[17]  Leisha M. Armijo,et al.  Intrathecal cannabilactone CB2R agonist, AM1710, controls pathological pain and restores basal cytokine levels , 2012, PAIN®.

[18]  Ellen C. Dengler,et al.  Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia , 2012, Brain and behavior.

[19]  A. Makriyannis,et al.  Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase. , 2012, Journal of proteome research.

[20]  A. Hohmann,et al.  The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy , 2012, Molecular pain.

[21]  B. Bahr,et al.  Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase – Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology , 2012, Neurotherapeutics.

[22]  A. Makriyannis,et al.  Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation. , 2011, Journal of proteome research.

[23]  A. Makriyannis,et al.  Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk , 2011, Expert opinion on drug discovery.

[24]  Z. Xi,et al.  Brain Cannabinoid CB2 Receptors Modulate Cocaine’s Actions in Mice , 2011, Nature Neuroscience.

[25]  A. Hohmann,et al.  Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: Antinociception without central nervous system side-effects , 2011, Pharmacology Biochemistry and Behavior.

[26]  J. Clemente,et al.  Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolution , 2011, Protein science : a publication of the Protein Society.

[27]  Shobha N. Bhattachar,et al.  Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. , 2011, ACS medicinal chemistry letters.

[28]  Lindsay K. Eller,et al.  The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat , 2011, Pharmacology Biochemistry and Behavior.

[29]  B. Bahr,et al.  A New Generation Fatty Acid Amide Hydrolase Inhibitor Protects Against Kainate-Induced Excitotoxicity , 2011, Journal of Molecular Neuroscience.

[30]  J. Salamone,et al.  The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior , 2010, Pharmacology Biochemistry and Behavior.

[31]  A. Makriyannis,et al.  hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation. , 2010, Chemistry & biology.

[32]  Anna L. Bowman,et al.  Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. , 2010, Journal of medicinal chemistry.

[33]  B. Lutz,et al.  A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents , 2010, British journal of pharmacology.

[34]  C. Limebeer,et al.  Inverse agonism of cannabinoid CB1 receptors potentiates LiCl‐induced nausea in the conditioned gaping model in rats , 2010, British journal of pharmacology.

[35]  S. Ambudkar,et al.  Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. , 2010, The Journal of clinical investigation.

[36]  A. Makriyannis,et al.  Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism. , 2010, Molecular bioSystems.

[37]  K. Mackie,et al.  Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[38]  A. Makriyannis,et al.  Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma , 2010, Journal of Lipid Research.

[39]  J. Salamone,et al.  The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats , 2010, Pharmacology Biochemistry and Behavior.

[40]  A. Makriyannis,et al.  Mass spectrometry-based GPCR proteomics: comprehensive characterization of the human cannabinoid 1 receptor. , 2010, Journal of proteome research.

[41]  J. Salamone,et al.  Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142 , 2010, European Neuropsychopharmacology.

[42]  A. Hohmann,et al.  Antinociceptive Effects of Racemic AM1241 and Its Chirally Synthesized Enantiomers: Lack of Dependence upon Opioid Receptor Activation , 2010, The AAPS Journal.

[43]  D. Nomura,et al.  Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo , 2009, Proceedings of the National Academy of Sciences.

[44]  Hong Zhang,et al.  Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis , 2009, Inflammatory bowel diseases.

[45]  S. Goldberg,et al.  The future of endocannabinoid-oriented clinical research after CB1 antagonists , 2009, Psychopharmacology.

[46]  J. Salamone,et al.  Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: Effects on food-reinforced behavior and comparisons with AM4113 , 2009, Pharmacology Biochemistry and Behavior.

[47]  Xiaoyu Tian.  Solid state NMR studies of interactions of cannabinergic ligands with lipid membrane systems , 2009 .

[48]  A. Makriyannis,et al.  Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog , 2009, Psychopharmacology.

[49]  Alexandros Makriyannis,et al.  Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. , 2008, Chemistry & biology.

[50]  J. Salamone,et al.  The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats , 2008, Behavioural Brain Research.

[51]  A. Makriyannis,et al.  Magnetically aligned bicelles to study the orientation of lipophilic ligands in membrane bilayers. , 2008, Journal of medicinal chemistry.

[52]  A. Hohmann,et al.  Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[53]  A. Makriyannis,et al.  Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. , 2008, Chemistry & biology.

[54]  A. Makriyannis,et al.  Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. , 2008, Journal of proteome research.

[55]  A. Makriyannis,et al.  Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties , 2008, Physiology & Behavior.

[56]  J. Salamone,et al.  The Novel Cannabinoid CB1 Receptor Neutral Antagonist AM4113 Suppresses Food Intake and Food-Reinforced Behavior but Does not Induce Signs of Nausea in Rats , 2008, Neuropsychopharmacology.

[57]  A. Zimmer,et al.  Cannabinoid receptors and the regulation of bone mass , 2008, British journal of pharmacology.

[58]  A. Makriyannis,et al.  Endocannabinoid metabolomics: A novel liquid chromatography-mass spectrometry reagent for fatty acid analysis , 2006, The AAPS Journal.

[59]  N. Volkow,et al.  Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand , 1999, AAPS PharmSci.

[60]  Alexandros Makriyannis,et al.  Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters , 2008, Clinical chemistry and laboratory medicine.

[61]  Q. Pittman,et al.  A neutral CB1 receptor antagonist reduces weight gain in rat. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[62]  C. George,et al.  Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. , 2007, Journal of medicinal chemistry.

[63]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[64]  Robin Christensen,et al.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials , 2007, The Lancet.

[65]  A. Hohmann,et al.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats , 2007, British journal of pharmacology.

[66]  A. Makriyannis,et al.  Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats , 2007, Behavioural pharmacology.

[67]  B. Bahr,et al.  Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage , 2007, Journal of Pharmacology and Experimental Therapeutics.

[68]  S. Nikas,et al.  C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. , 2007, Journal of medicinal chemistry.

[69]  J. Salamone,et al.  Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions , 2007, Physiology & Behavior.

[70]  B. Bahr,et al.  Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. , 2007, Analytical chemistry.

[71]  A. Makriyannis,et al.  Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor. , 2007, Journal of proteome research.

[72]  C. Fowler.  The cannabinoid system and its pharmacological manipulation – a review, with emphasis upon the uptake and hydrolysis of anandamide , 2006, Fundamental & clinical pharmacology.

[73]  T. Vanderah,et al.  CB2 cannabinoid receptor mediation of antinociception. , 2006, Pain.

[74]  A. Makriyannis,et al.  AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. , 2006, European journal of pharmacology.

[75]  B. Bahr,et al.  Targeting the endocannabinoid system in treating brain disorders , 2006, Expert opinion on investigational drugs.

[76]  J. Salamone,et al.  Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387 , 2006, Pharmacology Biochemistry and Behavior.

[77]  G. Uhl,et al.  Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain , 2006, Brain Research.

[78]  A. Makriyannis,et al.  (-)-7′-Isothiocyanato-11-hydroxy-1′,1′-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor , 2005, Molecular Pharmacology.

[79]  K. Mackie,et al.  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .

[80]  A. Makriyannis,et al.  High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. , 2005, Journal of medicinal chemistry.

[81]  W. Pierce,et al.  Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. , 2005, The journal of peptide research : official journal of the American Peptide Society.

[82]  A. Makriyannis,et al.  How lipophilic cannabinergic ligands reach their receptor sites. , 2005, Prostaglandins & other lipid mediators.

[83]  B. Bahr,et al.  Dual Modulation of Endocannabinoid Transport and Fatty Acid Amide Hydrolase Protects against Excitotoxicity , 2005, The Journal of Neuroscience.

[84]  A. Makriyannis,et al.  Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer. , 2005, Life sciences.

[85]  A. Makriyannis,et al.  The Conformation, Location, and Dynamic Properties of the Endocannabinoid Ligand Anandamide in a Membrane Bilayer* , 2005, Journal of Biological Chemistry.

[86]  J. Deschamps,et al.  Adamantyl cannabinoids: a novel class of cannabinergic ligands. , 2005, Journal of medicinal chemistry.

[87]  F. Rice,et al.  CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[88]  B. Bahr,et al.  Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. , 2005, European journal of pharmacology.

[89]  A. Makriyannis,et al.  Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system. , 2004, The journal of peptide research : official journal of the American Peptide Society.

[90]  A. Hohmann,et al.  Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. , 2004, Journal of neurophysiology.

[91]  Giovanni Piersanti,et al.  Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. , 2004, Journal of medicinal chemistry.

[92]  D. Fegley,et al.  Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[93]  A. Hohmann,et al.  Selective Activation of Cannabinoid CB2 Receptors Suppresses Hyperalgesia Evoked by Intradermal Capsaicin , 2004, Journal of Pharmacology and Experimental Therapeutics.

[94]  S. Nikas,et al.  Conformational study of lipophilic ligands in phospholipid model membrane systems by solution NMR. , 2003, Journal of medicinal chemistry.

[95]  T. Vanderah,et al.  Inhibition of Inflammatory Hyperalgesia by Activation of Peripheral CB2 Cannabinoid Receptors , 2003, Anesthesiology.

[96]  D. Cockayne,et al.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[97]  A. Hohmann,et al.  Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation , 2003, Neuroscience.

[98]  M. Tius,et al.  Synthesis of covalent probes for the radiolabeling of the cannabinoid receptor. , 2003, The Journal of organic chemistry.

[99]  T. Vanderah,et al.  Inhibition of pain responses by activation of CB(2) cannabinoid receptors. , 2002, Chemistry and physics of lipids.

[100]  A. Makriyannis,et al.  Ligand based structural studies of the CB1 cannabinoid receptor. , 2002, The journal of peptide research : official journal of the American Peptide Society.

[101]  Raymond C Stevens,et al.  Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.

[102]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[103]  Krzysztof Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Science.

[104]  N. Volkow,et al.  Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281 , 2000, Synapse.

[105]  R. Mechoulam,et al.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[106]  A. Makriyannis,et al.  High-resolution NMR and computer modeling studies of the cannabimimetic aminoalkylindole prototype WIN-55212-2. , 1999, Journal of medicinal chemistry.

[107]  D. Piomelli,et al.  Structural determinants for recognition and translocation by the anandamide transporter. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[108]  A. Makriyannis,et al.  Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. , 1999, Journal of medicinal chemistry.

[109]  A. Makriyannis,et al.  Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. , 1998, Journal of medicinal chemistry.

[110]  A. Makriyannis,et al.  Determination of anandamide amidase activity using ultraviolet-active amine derivatives and reverse-phase high-performance liquid chromatography. , 1998, Analytical biochemistry.

[111]  A. Makriyannis,et al.  Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling. , 1998, Journal of medicinal chemistry.

[112]  Payton King,et al.  Imaging the Brain Marijuana Receptor: Development of a Radioligand that Binds to Cannabinoid CB1 Receptors In Vivo , 1998, Journal of neurochemistry.

[113]  C. Qin.  Purification and characterization of anandamide amidase and development of novel inhibitors , 1998 .

[114]  D. Piomelli,et al.  Potentiation of anandamide hypotension by the transport inhibitor, AM404. , 1997, European journal of pharmacology.

[115]  D. Piomelli,et al.  Functional role of high-affinity anandamide transport, as revealed by selective inhibition. , 1997, Science.

[116]  W. A. Hill,et al.  Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. , 1997, Biochemical and biophysical research communications.

[117]  D. Deutsch,et al.  Inhibitors of anandamide breakdown. , 1997, NIDA research monograph.

[118]  T. Mavromoustakos,et al.  Topography and thermotropic properties of cannabinoids in brain sphingomyelin bilayers. , 1996, Life sciences.

[119]  W. A. Hill,et al.  Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. , 1996, Journal of medicinal chemistry.

[120]  W. A. Hill,et al.  High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. , 1996, Analytical biochemistry.

[121]  A. Makriyannis,et al.  The Conformational Properties of the Highly Selective Cannabinoid Receptor Ligand CP-55,940 (*) , 1996, The Journal of Biological Chemistry.

[122]  T. Mavromoustakos,et al.  Effects of the anesthetic steroid alphaxalone and its inactive delta 16-analog on the thermotropic properties of membrane bilayers. A model for membrane perturbation. , 1995, Biochimica et biophysica acta.

[123]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[124]  T. Mavromoustakos,et al.  Small angle X-ray diffraction and differential scanning calorimetric studies on O-methyl-(-)-delta 8-tetrahydrocannabinol and its 5' iodinated derivative in membrane bilayers. , 1995, Biochimica et biophysica acta.

[125]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[126]  J. Grzybowska,et al.  A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. , 1995, Life sciences.

[127]  A. Makriyannis,et al.  AM630, a competitive cannabinoid receptor antagonist. , 1995, Life sciences.

[128]  A. Makriyannis,et al.  (-)-11-Hydroxy-7'-isothiocyanato-1',1'-dimethylheptyl-delta 8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain. , 1994, Journal of medicinal chemistry.

[129]  T. Mavromoustakos,et al.  Topography of alphaxalone and Δ16-alphaxalone in membrane bilayers containing cholesterol , 1994 .

[130]  A. Makriyannis,et al.  (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. , 1994, Journal of medicinal chemistry.

[131]  A. Makriyannis,et al.  Conformational analysis of the prototype nonclassical cannabinoid CP-47,497, using 2D NMR and computer molecular modeling. , 1994, Journal of medicinal chemistry.

[132]  T. Mavromoustakos,et al.  Topography of alphaxalone and delta 16-alphaxalone in membrane bilayers containing cholesterol. , 1994, Biochimica et biophysica acta.

[133]  K. R. Jeffrey,et al.  Topography of tetrahydrocannabinol in model membranes using neutron diffraction. , 1993, Biochimica et biophysica acta.

[134]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[135]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[136]  A. Makriyannis,et al.  5'-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor. , 1992, Journal of medicinal chemistry.

[137]  T. Mavromoustakos,et al.  Amphipathic interactions of cannabinoids with membranes. A comparison between delta 8-THC and its O-methyl analog using differential scanning calorimetry, X-ray diffraction and solid state 2H-NMR. , 1992, Biochimica et biophysica acta.

[138]  A. Makriyannis,et al.  Solid state 2H-NMR as a method for determining the orientation of cannabinoid analogs in membranes , 1991, Pharmacology Biochemistry and Behavior.

[139]  T. Mavromoustakos,et al.  Small angle X-ray diffraction studies on the topography of cannabinoids in synaptic plasma membranes , 1991, Pharmacology Biochemistry and Behavior.

[140]  A. Makriyannis,et al.  Detection of cannabinoid receptors by photoaffinity labelling. , 1991, Biochemical and biophysical research communications.

[141]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[142]  T Mavromoustakos,et al.  Study of the topography of cannabinoids in model membranes using X-ray diffraction. , 1990, Biochimica et biophysica acta.

[143]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[144]  H. Jarrell,et al.  The orientation of (-)-delta 9-tetrahydrocannabinol in DPPC bilayers as determined from solid-state 2H-NMR. , 1989, Biochimica et biophysica acta.

[145]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[146]  R. Razdan,et al.  Structure-activity relationships of the cannabinoids. , 1986, NIDA research monograph.

[147]  S. Fesik,et al.  Mechanism of steroid anesthetic action: interactions of alphaxalone and delta 16-alphaxalone with bilayer vesicles. , 1983, Journal of medicinal chemistry.

[148]  M. Johnson,et al.  Levonantradol: A Role for Central Prostanoid Mechanisms? , 1981, Journal of clinical pharmacology.

[149]  D. W. Johnson,et al.  Cannabinoids. 3. Synthetic approaches to 9-ketocannabinoids. Total synthesis of nabilone. , 1977, The Journal of organic chemistry.

[150]  R. Mechoulam,et al.  Syntheses of .DELTA.1-tetrahydrocannabinol and related cannabinoids , 1972 .

[151]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[152]  S. Loewe,et al.  Tetrahydrocannabinol homologs with double branched alkyl groups in the 3-position. , 1948, Journal of the American Chemical Society.

[153]  S. Wilkinson,et al.  206. Cannabis indica. Part IV. The synthesis of some tetrahydrodibenzopyran derivatives , 1940 .